Rituximab biosimilar (Reliance Life Sciences)

利妥昔单抗生物类似药 (Reliance Life Sciences)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRituximab biosimilar (Reliance Life Sciences)

Drug Alias Name利妥昔单抗生物仿制药 (Reliance Life Sciences)Toritz RARituxiRelToritzR-TPR-017

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsArthritis, RheumatoidLymphoma, Non-Hodgkin

Global Approved IndicationsArthritis, RheumatoidLymphoma, Non-Hodgkin

Approved Indications in ChinaN/A

Original Approved Country/TerritoryIndia

Original Approved Date2016/01/01

Country/TerritoryIndia

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesReliance Life Sciences

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesN/A

Active IndicationsArthritis, RheumatoidLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeL01XC02